氯氮平可持续防止自杀行为,而其他抗精神病药物可能缺乏特定的保护作用:根据以往文献解读的 VigiBase 综合研究。

IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Carlos De Las Cuevas, Victoria C de Leon, Hilario Blasco-Fontecilla, Enrique Baca-García, Marina Sagud, Emilio J Sanz, Jose de Leon
{"title":"氯氮平可持续防止自杀行为,而其他抗精神病药物可能缺乏特定的保护作用:根据以往文献解读的 VigiBase 综合研究。","authors":"Carlos De Las Cuevas, Victoria C de Leon, Hilario Blasco-Fontecilla, Enrique Baca-García, Marina Sagud, Emilio J Sanz, Jose de Leon","doi":"10.1080/14740338.2024.2399094","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In the United States, clozapine was first approved for treatment-resistant schizophrenia and then for suicidality in schizophrenia psychoses. Systematic reviews support clozapine's anti-suicidal effect, but the forensic literature stresses its lethality during overdoses.</p><p><strong>Research design and methods: </strong>Clozapine reports to the international pharmacovigilance database (VigiBase) were analyzed for suicidal ideation, suicide attempts, intentional overdose, and completed suicides from introduction to 1 January 2024. VigiBase uses the information component (IC) as a disproportionality analysis.</p><p><strong>Results: </strong>The clozapine ICs (range: other antipsychotics) were: 1) suicidal ideation IC = 0.570 with IC<sub>025</sub> = 0.454 to IC<sub>975</sub> = 0.680 (IC = 3.568 for aripiprazole and 1.729 for risperidone), 2) suicide attempt IC = 1.428 with IC<sub>025</sub> = 1.323 to IC<sub>975</sub> = 1.529 (IC = 4.150 for quetiapine and 2.968 for risperidone), 3) intentional overdose: IC = 0.995 with IC<sub>025</sub> = 0.864 to IC<sub>975</sub> = 1.120 (IC = 4.080 for quetiapine and 1.957 for aripiprazole), and 4) completed suicide IC = 1.133 with IC<sub>025</sub> = 1.026 to IC<sub>975</sub> = 1.235 (IC = 4.648 for quetiapine and 2.160 for risperidone). In summary, all clozapine ICs were significantly lower. We found 2391 clozapine-treated patients on the suicidality spectrum (627 cases with suicidal ideation, 752 with suicide attempt, 488 with intentional overdose, and 731 with completed suicide) but many were taking other antipsychotics. The most frequent reporting countries were the United States, the United Kingdom, and Croatia.</p><p><strong>Conclusion: </strong>This pharmacovigilance study, with all its inherent limitations, provides independent proof, not overlapping with prior literature, that clozapine may have specific strong anti-suicidal effects that do not appear to be present in other antipsychotics. Further VigiBase studies are needed to compare the lethality of an intentional overdose of clozapine (14.3%) with other antipsychotics.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clozapine may consistently protect from suicidal behaviors while other antipsychotics may lack a specific protective effect: a comprehensive VigiBase study interpreted in the context of the prior literature.\",\"authors\":\"Carlos De Las Cuevas, Victoria C de Leon, Hilario Blasco-Fontecilla, Enrique Baca-García, Marina Sagud, Emilio J Sanz, Jose de Leon\",\"doi\":\"10.1080/14740338.2024.2399094\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>In the United States, clozapine was first approved for treatment-resistant schizophrenia and then for suicidality in schizophrenia psychoses. Systematic reviews support clozapine's anti-suicidal effect, but the forensic literature stresses its lethality during overdoses.</p><p><strong>Research design and methods: </strong>Clozapine reports to the international pharmacovigilance database (VigiBase) were analyzed for suicidal ideation, suicide attempts, intentional overdose, and completed suicides from introduction to 1 January 2024. VigiBase uses the information component (IC) as a disproportionality analysis.</p><p><strong>Results: </strong>The clozapine ICs (range: other antipsychotics) were: 1) suicidal ideation IC = 0.570 with IC<sub>025</sub> = 0.454 to IC<sub>975</sub> = 0.680 (IC = 3.568 for aripiprazole and 1.729 for risperidone), 2) suicide attempt IC = 1.428 with IC<sub>025</sub> = 1.323 to IC<sub>975</sub> = 1.529 (IC = 4.150 for quetiapine and 2.968 for risperidone), 3) intentional overdose: IC = 0.995 with IC<sub>025</sub> = 0.864 to IC<sub>975</sub> = 1.120 (IC = 4.080 for quetiapine and 1.957 for aripiprazole), and 4) completed suicide IC = 1.133 with IC<sub>025</sub> = 1.026 to IC<sub>975</sub> = 1.235 (IC = 4.648 for quetiapine and 2.160 for risperidone). In summary, all clozapine ICs were significantly lower. We found 2391 clozapine-treated patients on the suicidality spectrum (627 cases with suicidal ideation, 752 with suicide attempt, 488 with intentional overdose, and 731 with completed suicide) but many were taking other antipsychotics. The most frequent reporting countries were the United States, the United Kingdom, and Croatia.</p><p><strong>Conclusion: </strong>This pharmacovigilance study, with all its inherent limitations, provides independent proof, not overlapping with prior literature, that clozapine may have specific strong anti-suicidal effects that do not appear to be present in other antipsychotics. Further VigiBase studies are needed to compare the lethality of an intentional overdose of clozapine (14.3%) with other antipsychotics.</p>\",\"PeriodicalId\":12232,\"journal\":{\"name\":\"Expert Opinion on Drug Safety\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-09-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Opinion on Drug Safety\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14740338.2024.2399094\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14740338.2024.2399094","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

背景:在美国,氯氮平首先被批准用于治疗耐药性精神分裂症,然后被批准用于治疗精神分裂症精神病患者的自杀倾向。系统综述支持氯氮平的抗自杀作用,但法医文献强调其在过量用药时的致命性:对国际药物警戒数据库(VigiBase)中的氯氮平报告进行分析,以了解从引入到 2024 年 1 月 1 日期间的自杀意念、自杀未遂、故意用药过量和自杀完成情况。VigiBase 使用信息成分(IC)进行比例失调分析:结果:氯氮平的 IC(范围:其他抗精神病药物)为1)自杀意念 IC = 0.570,IC025 = 0.454 至 IC975 = 0.680(阿立哌唑的 IC = 3.568,利培酮的 IC = 1.729);2)自杀未遂 IC = 1.428,IC025 = 1.323 至 IC975 = 1.529(喹硫平的 IC = 4.150,利培酮的 IC = 2.968);3)自杀倾向 IC = 0.570,IC025 = 0.454 至 IC975 = 0.680(阿立哌唑的 IC = 3.568,利培酮的 IC = 1.729)。3) 故意用药过量:IC = 0.995,IC025 = 0.864 至 IC975 = 1.120(喹硫平的 IC = 4.080,阿立哌唑的 IC = 1.957),以及 4) 完成自杀:IC = 1.133,IC025 = 1.026 至 IC975 = 1.235(喹硫平的 IC = 4.648,利培酮的 IC = 2.160)。总之,所有氯氮平的 IC 均显著降低。我们发现有 2391 例接受氯氮平治疗的患者有自杀倾向(627 例有自杀意念,752 例自杀未遂,488 例故意用药过量,731 例自杀完成),但其中许多人正在服用其他抗精神病药物。报告最多的国家是美国、英国和克罗地亚:这项药物警戒研究虽然有其固有的局限性,但它提供了独立的证据,证明氯氮平可能具有其他抗精神病药物所不具有的特殊的强烈抗自杀作用。还需要进一步开展 VigiBase 研究,以比较故意过量服用氯氮平(14.3%)与其他抗精神病药物的致死率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Clozapine may consistently protect from suicidal behaviors while other antipsychotics may lack a specific protective effect: a comprehensive VigiBase study interpreted in the context of the prior literature.

Background: In the United States, clozapine was first approved for treatment-resistant schizophrenia and then for suicidality in schizophrenia psychoses. Systematic reviews support clozapine's anti-suicidal effect, but the forensic literature stresses its lethality during overdoses.

Research design and methods: Clozapine reports to the international pharmacovigilance database (VigiBase) were analyzed for suicidal ideation, suicide attempts, intentional overdose, and completed suicides from introduction to 1 January 2024. VigiBase uses the information component (IC) as a disproportionality analysis.

Results: The clozapine ICs (range: other antipsychotics) were: 1) suicidal ideation IC = 0.570 with IC025 = 0.454 to IC975 = 0.680 (IC = 3.568 for aripiprazole and 1.729 for risperidone), 2) suicide attempt IC = 1.428 with IC025 = 1.323 to IC975 = 1.529 (IC = 4.150 for quetiapine and 2.968 for risperidone), 3) intentional overdose: IC = 0.995 with IC025 = 0.864 to IC975 = 1.120 (IC = 4.080 for quetiapine and 1.957 for aripiprazole), and 4) completed suicide IC = 1.133 with IC025 = 1.026 to IC975 = 1.235 (IC = 4.648 for quetiapine and 2.160 for risperidone). In summary, all clozapine ICs were significantly lower. We found 2391 clozapine-treated patients on the suicidality spectrum (627 cases with suicidal ideation, 752 with suicide attempt, 488 with intentional overdose, and 731 with completed suicide) but many were taking other antipsychotics. The most frequent reporting countries were the United States, the United Kingdom, and Croatia.

Conclusion: This pharmacovigilance study, with all its inherent limitations, provides independent proof, not overlapping with prior literature, that clozapine may have specific strong anti-suicidal effects that do not appear to be present in other antipsychotics. Further VigiBase studies are needed to compare the lethality of an intentional overdose of clozapine (14.3%) with other antipsychotics.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.90
自引率
3.20%
发文量
97
审稿时长
6-12 weeks
期刊介绍: Expert Opinion on Drug Safety ranks #62 of 216 in the Pharmacology & Pharmacy category in the 2008 ISI Journal Citation Reports. Expert Opinion on Drug Safety (ISSN 1474-0338 [print], 1744-764X [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on all aspects of drug safety and original papers on the clinical implications of drug treatment safety issues, providing expert opinion on the scope for future development.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信